Free Trial

United Therapeutics (NASDAQ:UTHR) Stock Rating Lowered by StockNews.com

United Therapeutics logo with Medical background

United Therapeutics (NASDAQ:UTHR - Get Free Report) was downgraded by investment analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research report issued on Thursday.

Several other equities research analysts have also issued reports on UTHR. Oppenheimer boosted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, October 31st. HC Wainwright upped their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. The Goldman Sachs Group increased their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research report on Friday, November 1st. Argus lifted their price objective on United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Finally, TD Cowen increased their target price on United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $370.86.

View Our Latest Research Report on United Therapeutics

United Therapeutics Stock Performance

Shares of UTHR traded up $2.61 during trading hours on Thursday, reaching $360.16. 335,081 shares of the company traded hands, compared to its average volume of 446,780. United Therapeutics has a 1-year low of $208.62 and a 1-year high of $417.82. The stock has a market cap of $16.08 billion, a P/E ratio of 15.82, a price-to-earnings-growth ratio of 1.05 and a beta of 0.54. The stock's fifty day moving average is $371.01 and its 200 day moving average is $344.37.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company's quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter last year, the company earned $5.38 EPS. On average, equities research analysts predict that United Therapeutics will post 25.22 EPS for the current year.

Insiders Place Their Bets

In other news, CFO James Edgemond sold 7,800 shares of United Therapeutics stock in a transaction on Monday, October 28th. The stock was sold at an average price of $350.00, for a total value of $2,730,000.00. Following the completion of the sale, the chief financial officer now directly owns 6,978 shares of the company's stock, valued at approximately $2,442,300. This trade represents a 52.78 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Louis W. Sullivan sold 26,209 shares of the company's stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total value of $9,781,722.98. Following the transaction, the director now directly owns 5,051 shares in the company, valued at $1,885,134.22. This trade represents a 83.84 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 145,549 shares of company stock valued at $54,547,253. Insiders own 11.90% of the company's stock.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently modified their holdings of the business. ClariVest Asset Management LLC boosted its stake in United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock valued at $25,000 after acquiring an additional 42 shares during the last quarter. Innealta Capital LLC bought a new position in United Therapeutics during the second quarter worth about $33,000. USA Financial Formulas acquired a new position in shares of United Therapeutics during the 3rd quarter worth about $33,000. Brooklyn Investment Group acquired a new position in shares of United Therapeutics during the 3rd quarter worth about $33,000. Finally, Capital Performance Advisors LLP bought a new stake in shares of United Therapeutics in the 3rd quarter valued at about $82,000. Institutional investors and hedge funds own 94.08% of the company's stock.

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Stories

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in United Therapeutics right now?

Before you consider United Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.

While United Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines